NCT00145301View on ClinicalTrials.gov

52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine

PHASE3CompletedINTERVENTIONAL

Enrollment

3,036

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2005

Conditions

Osteoarthritis

Interventions

DRUG

Lumiracoxib

Trial Locations (1)

Unknown

Novartis, Nuremberg

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY

NCT00145301 - 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine | Biotech Hunter | Biotech Hunter